MEDP vs ICLR vs CRL vs PRA vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -2. 7% for ProAssurance Corporation (PRA). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 7x forward), making it the more compelling value choice. Analysts rate ICON Public Limited Company (ICLR) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus Hims & Hers Health, Inc. at 55. 4x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 78x versus ICON Public Limited Company's 1. 53x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -46. 6% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: MEDP returned +1426% versus PRA's -18. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ProAssurance Corporation (PRA) is the lower-risk stock at 0.

05β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 4934% more volatile than PRA relative to the S&P 500. On balance sheet safety, ProAssurance Corporation (PRA) carries a lower debt/equity ratio of 32% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -2. 7% for ProAssurance Corporation (PRA). On earnings-per-share growth, the picture is similar: ICON Public Limited Company grew EPS 28. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus 5. 2% for HIMS. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 78x versus ICON Public Limited Company's 1. 53x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 7x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 47. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ICLR: 22. 2% to $152. 13.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ProAssurance Corporation (PRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRA: -18. 6%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MEDP (Healthcare) and ICLR (Healthcare) and CRL (Healthcare) and PRA (Financial Services) and HIMS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MEDP is a mid-cap high-growth stock; ICLR is a small-cap deep-value stock; CRL is a small-cap quality compounder stock; PRA is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.